News & Events

Investor Center

Careers

Pipeline

Partnership

About  Us

About Us

Research & Development

Research & Development Pipeline Partership Investor Center News & Events Careers
Home

中文

Contact
   Home    Home-Ch
Press Releases
More Ascletis News
News & Events    Home-Ch
© 2016 Ascletis. All Rights Reserved
浙公网安备 33010802003344 号
CONTACT US
pr@ascletis.com
hr@ascletis.com
bd@ascletis.com
clinicaltrials@ascletis.com
Contact

Jan 03, 2017   Ascletis Raises US$100 Million in Series B Financing >>

20170103AscletisSeriesBfinancing.pdf

May 27, 2016   Party Secretary of ShaoXing Mr. Peng Jiaxue Visited Ascletis  >>

20170526Peng.pdf

Feb 22, 2017   Commissioner Zhiquan Zhu of CFDA  Zhejiang Bureau Visited Ascletis  >>

20170222ZJCFDA.pdf

Feb 19, 2017   Ascletis Presented at the 26th APASL Annual Meeting and Held Successfully “China - developed DAAs”  Symposium >>

20170219APASL.pdf

Mar 06, 2017   Danoprevir NDA Designated for Priority Review by CFDA  >>

20170306PriorityReview.pdf

May 21, 2017   Dr.Jinzi Wu Spoke at the 9th DIA China Annual Meeting   >>

20170521DIA.pdf
CCTV Report on HCV
Partnership
IHEPA Interview
Partership XinyueChen.pdf

Guidelines for the HCV Treatment

GuidelinesForHCV2015.pdf

Danoprevir

HIV in China
Video
Corporate Member

Ascletis is a specialty therapeutics company dedicated to discovering

and developing important new treatments for cancer and infectious diseases.

HCV IN CHINA

歌礼与您携手

共同抗击肝炎

Together, Cure Hepatitis

7.28 世界肝炎日

World Hepatitis Day